Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Arrowhead Pharmaceuticals announced that its drug Redemplo® (Plozasiran) has received marketing authorization from the European Commission for lowering triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS).

Arrowhead Pharmaceuticals announced that its drug Redemplo® (Plozasiran) has received marketing authorization from the European Commission for lowering triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS).

老虎证券老虎证券2026/06/22 16:52
Show original
FCS is a rare and severe genetic disease characterized by extremely high levels of triglycerides in the blood, which can lead to life-threatening pancreatitis. This approval marks a significant advancement for Arrowhead Pharmaceuticals in the field of rare disease treatments, providing a new treatment option for FCS patients in Europe. The company stated that it is committed to bringing this innovative therapy to patients in need as soon as possible.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

South Korean think tanks significantly raise 2027 economic growth forecasts, betting on continued AI chip boom

The Korea Development Institute (KDI) raised its economic growth forecast for this year and next on Wednesday, betting that the global artificial intelligence (AI) boom will continue to drive semiconductor exports and investment, helping the South Korean economy maintain its growth momentum.

智通财经•2026/11/18 04:12

SQM.US Q3 profit misses expectations; lithium price declines but demand outlook remains “encouraging”

SQM.US still reports seeing "encouraging" potential demand trends.

智通财经•2026/11/18 03:16